This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I26 (Pulmonary embolism) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Pulmonary thromboembolism (PTE), pulmonary artery embolism, massive/submassive/low-risk PE |
| C. Adult onset | Presents mainly from adulthood; a disease in which thrombi, mostly originating from deep vein thrombosis (DVT), occlude the pulmonary arteries, closely associated with risk factors such as advanced age, surgery, malignancy, and immobilization. |
| 1. History | Development from Virchow's triad theory of thrombosis (1856) through the introduction of heparin and warfarin, the era of direct oral anticoagulants, and ESC risk stratification strategies |
| 2. Causes | Virchow's triad (venous stasis, endothelial injury, hypercoagulable state); surgery, cancer, immobilization, oral contraceptives, pregnancy, congenital thrombophilia |
| 3. Genetics | Factor V Leiden, prothrombin G20210A, MTHFR C677T, protein C/S deficiency, and antithrombin deficiency are the main genetic risk factors |
| 4. General epidemiology | Annual incidence in the West 100–200 per 1 million; recently increasing in Korea; third leading cause of cardiovascular death; high rate of missed diagnosis |
| 5. Pathophysiology | DVT thrombus dislodgement → pulmonary artery occlusion → sharp rise in right ventricular afterload → right ventricular failure → septal compression → reduced left ventricular filling → shock |
| 6. Symptoms | Sudden dyspnea, pleuritic chest pain, cough, and hemoptysis are typical; in massive pulmonary embolism, syncope and cardiogenic shock also occur |
| 7. Signs | Tachypnea, tachycardia, hypoxemia, jugular venous distension, accentuated pulmonic S2, signs of lower limb DVT (swelling, redness, tenderness), etc. |
| 8. Screening | Estimation of pretest probability using the Wells score and Geneva score; D-dimer testing useful for excluding low-risk patients |
| 9. Diagnosis | CTPA (CT pulmonary angiography) is the standard diagnostic test; ventilation-perfusion scan, echocardiography, and lower limb venous compression ultrasound are also used |
| 10. Treatment | Depending on risk, choice of DOAC anticoagulation alone, heparin bridging therapy, systemic thrombolysis, catheter-directed therapy, or surgical embolectomy |
| 11. Prognosis | In-hospital mortality of high-risk (massive) pulmonary embolism 15–30%; very good with appropriate anticoagulation in the low-risk group; watch for chronic thromboembolic pulmonary hypertension |
| 12. Prevention | Early ambulation after surgery, mechanical and pharmacological thromboprophylaxis, DOAC prophylaxis in cancer patients, anticoagulant prophylaxis strategies for people with hereditary thrombophilia |
| 13. References | Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism … and 9 other papers |
The historical understanding of pulmonary embolism derives from the work of the 19th-century German pathologist Rudolf Virchow. In 1856, Virchow proposed "Virchow's triad", which theorized the three conditions necessary for thrombus formation: venous stasis, endothelial injury, and a hypercoagulable state of the blood. He was also the first to systematically describe the mechanism by which thrombi in the pulmonary arteries originate in the veins of the lower limbs and reach the lungs as emboli. This theory remains, 170 years later, the foundation of the pathophysiology of deep vein thrombosis (DVT) and pulmonary embolism.
Until the early 20th century, pulmonary embolism was confirmed only as a pathological finding, but the discovery of heparin in 1916 (Jay McLean, Johns Hopkins) and the clinical introduction of warfarin in the 1940s made therapeutic anticoagulation possible for the first time. In the 1960s, ventilation-perfusion scanning (V/Q scan) using radioisotopes was introduced, enabling noninvasive diagnosis of pulmonary embolism, and with the development of spiral CT in 1992, CT pulmonary angiography (CTPA) became established as the new standard diagnostic test. The PIOPED study (1990) and PIOPED II study (2006) systematically evaluated the diagnostic accuracy of V/Q scanning and CTPA, respectively, laying the evidence base for modern diagnostic algorithms.
The development of clinical decision tools also brought important progress in the management of pulmonary embolism. The Wells score developed by Philip Wells in 1998 and the later Geneva score contributed to systematically estimating pretest probability (PTP), reducing unnecessary testing, and optimizing the use of D-dimer testing. Clinical use of D-dimer began in the 1980s, and diagnostic efficiency has greatly improved with the development of high-sensitivity assays and the introduction of an age-adjusted cutoff (age × 10 μg/L).
Since the 2000s, the development of direct oral anticoagulants (DOACs: rivaroxaban, apixaban, edoxaban, dabigatran) has brought revolutionary change to the treatment of pulmonary embolism. The EINSTEIN-PE (rivaroxaban), AMPLIFY (apixaban), HOKUSAI-VTE (edoxaban), and RE-COVER (dabigatran) studies demonstrated that DOACs are noninferior to conventional unfractionated heparin/warfarin therapy with a lower bleeding risk. The 2019 ESC guidelines recommended DOACs as first-line treatment for non-cancer pulmonary embolism, and guidelines for cancer patients were also revised to reflect the results of the SELECT-D and ADAM VTE studies, which showed that DOACs are superior to warfarin in cancer-associated thrombosis as well.
Recently, technical advances in catheter-directed therapy (CDT) and pulmonary embolectomy have expanded new treatment options for high-risk or intermediate-high-risk pulmonary embolism. The concept of the Pulmonary Embolism Response Team (PERT) has been introduced, emphasizing a multidisciplinary approach. The establishment of pulmonary endarterectomy and riociguat therapy for chronic thromboembolic pulmonary hypertension (CTEPH) is also an important advance in long-term management.
The root cause of pulmonary embolism is the combined action of the three conditions of Virchow's triad. First, venous stasis occurs with prolonged immobilization (surgery, long-haul flights, paralysis, cast immobilization), heart failure, venous insufficiency, and obesity. When blood flow velocity decreases, the local concentration of activated coagulation factors rises and platelets remain in contact with the vessel wall longer, promoting thrombus formation. Second, endothelial injury occurs with surgery, trauma, venipuncture, catheter insertion, and venous inflammation (thrombophlebitis), and exposed subendothelial collagen and tissue factor trigger the coagulation cascade.
Third, hypercoagulability is divided into congenital (hereditary thrombophilia) and acquired causes. Acquired causes of hypercoagulability include malignancy (mucin-producing adenocarcinoma, hematologic malignancies, etc.), pregnancy and the postpartum period, estrogen-containing oral contraceptives and hormone replacement therapy, antiphospholipid syndrome, thrombocytosis (including myeloproliferative disorder), nephrotic syndrome (antithrombin loss), heart failure, sepsis, autoimmune diseases, and paroxysmal nocturnal hemoglobinuria (PNH).
Risk factors for pulmonary embolism are classified by strength into high, intermediate, and low risk. High-risk factors include major orthopedic surgery (hip replacement, knee replacement), major pelvic or abdominal surgery, bone marrow transplantation, spinal cord injury, pelvic or lower limb fracture, lower limb paralysis, and malignancy (especially advanced cancer). Intermediate-risk factors include venous surgery below the popliteal vein, central venous catheters, chemotherapy, heart or respiratory failure, a previous history of VTE, pregnancy/the postpartum period, estrogen-containing contraceptives, and autoimmune diseases. Low-risk factors include bed rest of 3 days or more, long-distance travel, advanced age, obesity, smoking, and varicose veins.
Hereditary thrombophilia is an important genetic risk factor for venous thromboembolism (VTE), including pulmonary embolism. The most common and best-known genetic variant is the Factor V Leiden (FVL) mutation, in which arginine 506 of coagulation factor V is replaced by glutamine (G1691A). This variant impedes inactivation of factor Va by activated protein C (APC), causing a hypercoagulable state. VTE risk is increased 5–10-fold in heterozygous carriers and 50–100-fold in homozygous carriers. FVL occurs at a frequency of about 5% in people of European ancestry and less than about 1% in Koreans.
The prothrombin G20210A mutation is the second most common hereditary thrombophilia; a variant in the 3' untranslated region of the prothrombin gene increases the plasma prothrombin concentration, promoting thrombus formation. VTE risk in heterozygous carriers is increased about 2–4-fold, and it occurs at a frequency of about 2–3% in people of European ancestry but is very rare in East Asians. The MTHFR (methylenetetrahydrofolate reductase) C677T variant, when homozygous, can cause hyperhomocysteinemia and increase VTE risk, but a direct causal relationship is controversial.
Protein C deficiency is an autosomal dominant disorder in which reduced APC generation results in insufficient inactivation of factors Va and VIIIa. VTE risk is increased about 3–10-fold, and it rarely causes neonatal purpura fulminans. Protein S deficiency shows a similar hypercoagulable phenotype due to deficiency of protein S, a cofactor of APC. Antithrombin (AT) deficiency is the hereditary thrombophilia with the strongest thrombotic risk; even heterozygous carriers have a 15–25-fold increased VTE risk, and it can cause resistance to heparin therapy. Testing for these genetic variants is performed especially in cases of unexplained thrombosis at a young age, recurrent VTE, thrombosis at atypical sites, or a family history.
Pulmonary embolism is reported to occur at 100–200 cases per 1 million per year in Western countries and is the third leading cause of cardiovascular death after heart disease and stroke. In the United States, about 600,000–800,000 cases of VTE occur annually, of which deaths due to pulmonary embolism are estimated at about 100,000 per year. Because many cases go undiagnosed, the actual incidence is estimated to be higher. Autopsy studies report that about 10–15% of in-hospital deaths are due to pulmonary embolism.
In Korea, the incidence of pulmonary embolism was lower than in the West, but it has recently been increasing sharply due to population aging, rising obesity, increasing numbers of surgeries, and growing numbers of cancer survivors. According to Health Insurance Review & Assessment Service (HIRA) data, the number of inpatients with pulmonary embolism more than doubled over the 2010s. In-hospital pulmonary embolism in Korea includes a considerable proportion of cases related especially to surgery and cancer.
Differences by age and sex are also clear. The incidence of pulmonary embolism increases exponentially with age, reaching more than 800 cases per 1 million in those aged 80 and older. Under age 40, incidence is similar in men and women or tends to be slightly higher in women (effects of oral contraceptives and pregnancy), whereas over age 40, men show a slightly higher incidence. The ratio of primary (idiopathic) to secondary (provoked) pulmonary embolism is reported to be about 40:60. Cancer-associated pulmonary embolism accounts for about 20% of the total, and VTE is the second most common cause of death in cancer patients.
The recurrence rate is also clinically important. The 5-year recurrence rate after stopping anticoagulant therapy is about 30% and is higher in unprovoked pulmonary embolism. Recurrent pulmonary embolism is a major risk factor for chronic thromboembolic pulmonary hypertension (CTEPH), and CTEPH develops in about 4% within 2 years of pulmonary embolism.
The pathophysiology of pulmonary embolism is a chain reaction leading from thromboembolism → pulmonary artery occlusion → right ventricular dysfunction → hemodynamic collapse. Most pulmonary emboli arise when thrombi formed in the deep veins of the lower limbs (popliteal vein or above) break off, travel through the venous system to the right atrium → right ventricle → pulmonary artery, and occlude the pulmonary artery. Rarely, thrombi originate in the upper limb veins, pelvic veins, right atrium, or right ventricle.
When the pulmonary artery is occluded, pulmonary vascular resistance (PVR) increases sharply. This is worsened not only by simple mechanical obstruction but also by additional vasospasm due to hypoxemia and vasoactive substances (serotonin, histamine, thromboxane A2). Faced with a sudden increase in afterload, the right ventricle attempts to compensate through dilation and increased contractility, but if adaptation fails, it progresses to right ventricular failure.
The dilated right ventricle pushes the interventricular septum toward the left ventricle, producing the "D-sign" (septal shift). This impairs diastolic filling of the left ventricle, reducing left ventricular output (pericardial constraint mechanism), and coronary perfusion pressure also falls. Right ventricular myocardial oxygen demand rises sharply while right coronary perfusion pressure decreases, causing right ventricular myocardial ischemia, which forms a vicious cycle that further worsens right ventricular failure.
Impaired gas exchange is also an important mechanism. In the vascular territory occluded by thrombus, ventilation is maintained but there is no perfusion, so dead space increases, resulting in decreased PaCO2 (hyperventilatory compensation) and hypoxemia. In some patients, reflex bronchospasm, alveolar collapse (loss of surfactant), and reactive pulmonary arteriovenous shunting (AV shunt) further worsen hypoxemia. In massive pulmonary embolism, these pathophysiological changes progress rapidly and can lead to cardiogenic shock within minutes to hours.
The symptoms of pulmonary embolism vary widely from asymptomatic to sudden death depending on the site and extent of occlusion and the underlying cardiopulmonary function. The classic triad of symptoms is sudden dyspnea, pleuritic chest pain, and hemoptysis, but all three occur in less than 20% of cases. Dyspnea is the most common symptom, occurring in about 80–90%, and is characterized by sudden onset and persistence even at rest.
Pleuritic chest pain occurs mainly in peripheral pulmonary embolism and is caused by pleural irritation due to pulmonary infarction. It is a sharp pain that worsens on inspiration, and there may be local tenderness when pressing over the pleura. Absence of chest pain is more common in central massive pulmonary embolism. Hemoptysis occurs with accompanying pulmonary infarction and is generally small in amount.
In massive pulmonary embolism, syncope and cardiogenic shock may occur. Syncope is due to a sudden decrease in cardiac output and reduced cerebral perfusion and is an ominous sign suggesting a high risk of death. Cardiogenic shock presents with hypotension (systolic blood pressure <90mmHg or a drop of 40mmHg or more), pallor, cold sweat, altered consciousness, and oliguria. Ventricular arrhythmias may also occur and may lead to cardiac arrest in the form of pulseless electrical activity (PEA).
Nonspecific symptoms may include anxiety, cough (dry), fever (38℃ or lower), and palpitations. In subacute or small pulmonary embolism, symptoms may be very mild, or only vague dyspnea and exercise intolerance lasting for weeks may appear, so diagnosis is sometimes delayed. Symptoms of lower limb DVT (unilateral leg swelling, redness, pain) are present in about 40–50%.
Physical findings of pulmonary embolism are nonspecific, but a combination of signs provides clues to the diagnosis. The most common sign is tachypnea (respiratory rate >20/min), present in about 70%, and tachycardia (heart rate >100/min) is also frequent. Decreased oxygen saturation (SpO2 <95%) appears in moderate or more severe pulmonary embolism, and cyanosis is a sign of severe hypoxemia.
On auscultation, crackles or a friction rub may be heard over the lung fields (with accompanying pulmonary infarction), and an accentuated pulmonic component of S2 (louder P2) reflects elevated pulmonary artery pressure. In severe right ventricular failure, a tricuspid regurgitation murmur, jugular venous distension (elevated JVP), hepatomegaly (hepatojugular reflux sign), and an S3 gallop rhythm may appear. In massive pulmonary embolism, markedly elevated jugular venous pressure, hypotension, cold and pale extremities, and altered consciousness are observed.
As signs of accompanying DVT, unilateral leg swelling, redness, warmth, and tenderness may be observed. Homans' sign (calf pain on ankle dorsiflexion) has low sensitivity and specificity, so its diagnostic value is limited. Tenderness along the femoral vein or a palpable cord-like induration strongly suggests DVT. Pulsus paradoxus can appear in massive pulmonary embolism even without cardiac tamponade, which is related to reduced left ventricular compliance due to septal shift.
The diagnostic algorithm for pulmonary embolism begins with assessment of clinical pretest probability (PTP). The Wells score consists of 7 variables: clinical signs of DVT (3 points), an alternative diagnosis less likely than PE (3 points), heart rate >100/min (1.5 points), immobilization for 3 days or more or surgery within 4 weeks (1.5 points), previous DVT/PE (1.5 points), hemoptysis (1 point), and malignancy (1 point); 4 points or less is classified as PE unlikely and more than 4 points as PE likely. In the dichotomous classification, 4 points or less is judged as low probability (PE less than 40%).
The revised Geneva score consists only of objective variables, so interobserver variability is low. It sums age 65 or older (1 point), previous DVT/PE (3 points), surgery or fracture within 1 month (2 points), malignancy (2 points), unilateral lower limb pain (3 points), hemoptysis (2 points), heart rate 75–94 (3 points) or 95 or more (5 points), and pain on deep venous palpation of the lower limb with unilateral edema (4 points). In patients with low-risk PTP, if a high-sensitivity D-dimer test is negative (below the age-adjusted cutoff), pulmonary embolism can be excluded without further imaging.
The PERC (Pulmonary Embolism Rule-out Criteria) rule is a tool that can exclude pulmonary embolism without D-dimer testing in low-probability patients who satisfy all 8 clinical variables (age <50 years, heart rate <100, SpO2 ≥95%, no unilateral leg swelling, no hemoptysis, no surgery/trauma, no previous VTE, no oral estrogen use). The 12-lead electrocardiogram is also important for severity assessment, and an S1Q3T3 pattern, new right bundle branch block, atrial fibrillation, etc. suggest right heart strain.
CT pulmonary angiography (CTPA) is the standard diagnostic test for pulmonary embolism. Using multislice CT (MDCT), filling defects within the pulmonary arteries are directly visualized, and emboli at the segmental pulmonary artery level or above can be detected with a sensitivity and specificity of about 90–95%. CTPA can simultaneously evaluate other causative conditions of the lung parenchyma, pleura, mediastinum, etc., which is advantageous for differential diagnosis. The CT right ventricle/left ventricle short-axis ratio (RV/LV ratio >0.9) is used to quantify right heart strain.
A ventilation-perfusion scan (V/Q scan) is used as an alternative to CTPA in cases of contrast allergy, severe renal impairment, or when minimizing radiation exposure during pregnancy is needed. A high-probability V/Q scan (perfusion defects in 2 or more segments) has high diagnostic value, and a normal scan excludes pulmonary embolism. A disadvantage is the high number of indeterminate results. Lower limb venous compression ultrasonography (CUS) is the first-line test for diagnosing DVT, and when DVT is confirmed in a patient with suspected pulmonary embolism, it provides grounds for starting anticoagulant therapy.
Echocardiography is used for rapid assessment of right ventricular function when CTPA is difficult to perform in hemodynamically unstable patients and can identify right ventricular dilation, dysfunction, and paradoxical septal motion. McConnell's sign (right ventricular free wall hypokinesis + apical hyperkinesis) is relatively specific for pulmonary embolism. Elevated troponin (I/T) and BNP/NT-proBNP reflect right ventricular injury and overload and are used for prognostic prediction. Conventional pulmonary angiography was formerly the standard test but, because of its invasiveness, is now used only when planning catheter-based treatment.
The cornerstone of pulmonary embolism treatment is anticoagulant therapy, and the intensity and method of treatment are determined according to risk classification. The 2019 ESC guidelines classify pulmonary embolism as high risk (with shock/hypotension), intermediate-high risk (right ventricular dysfunction + elevated troponin), intermediate-low risk, and low risk.
In low-risk and intermediate-low-risk patients, a DOAC (rivaroxaban 15mg twice/day × 3 weeks then 20mg once/day, or apixaban 10mg twice/day × 1 week then 5mg twice/day) is the first-line treatment. Initial unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) followed by transition to warfarin is also effective. The duration of anticoagulation is at least 3 months for a first provoked pulmonary embolism, and long-term or indefinite therapy is considered for unprovoked or recurrent pulmonary embolism.
In intermediate-high-risk patients, anticoagulation is started with UFH, and hemodynamic status is closely monitored in preparation for switching to reperfusion therapy if deterioration occurs. In high-risk (massive) pulmonary embolism, immediate systemic thrombolysis (rt-PA 100mg IV over 2 hours) is the first choice. When thrombolysis is absolutely contraindicated or has failed, surgical pulmonary embolectomy is performed. Catheter-directed low-dose thrombolysis (CDT) or hemodynamic support (ECMO) is also an option. Oxygen supplementation, fluid therapy (maintaining adequate preload), and vasopressors (norepinephrine preferred) are given as supportive treatment.
Inferior vena cava filters (IVC filters) are applied on a limited basis when anticoagulation is absolutely contraindicated or when recurrence occurs during anticoagulant therapy. In pulmonary embolism in cancer patients, DOACs (edoxaban, rivaroxaban) show results similar to or slightly better than LMWH, and in gastrointestinal cancers with a high risk of mucosal bleeding, LMWH is safer. The decision to stop anticoagulation is individualized by balancing the risk of recurrence (presence of VTE-provoking factors, D-dimer, residual thrombus on imaging) and the risk of bleeding.
The prognosis of pulmonary embolism differs greatly according to severity classification. In-hospital mortality of high-risk (massive) pulmonary embolism reaches 15–30%, and up to 50% has been reported when accompanied by shock. Immediate thrombolysis or surgical embolectomy is key in determining survival. In-hospital mortality of intermediate-high-risk patients is about 3–15%, and if hemodynamic deterioration occurs, an immediate switch to reperfusion therapy is needed.
Low-risk and intermediate-low-risk patients have a good prognosis, with in-hospital mortality below 1% when they receive appropriate anticoagulant therapy. Low-risk patients with a low PESI (Pulmonary Embolism Severity Index) score (class I–II) can be treated as outpatients or discharged early, supported by the results of the HOME-PE study (2021).
The most important long-term complication is chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH develops in about 2–4% within 2 years after pulmonary embolism and is caused by incomplete thrombus resolution, mechanical pulmonary artery obstruction, and small artery remodeling. Pulmonary endarterectomy (PEA) is the curative treatment for operable CTEPH, and riociguat is used when surgery is not possible or residual pulmonary hypertension persists. In addition, post-thrombotic syndrome (PTS) is a long-term complication of DVT that causes chronic leg edema, skin discoloration, and venous ulcers.
The risk of recurrence varies with the duration of anticoagulant therapy; when therapy is stopped after 3 months, the 10-year recurrence rate reaches about 30–50%. Unprovoked pulmonary embolism, recurrent VTE, male sex, residual thrombus, and persistently elevated D-dimer are high-risk factors for recurrence. Risk prediction models such as DASH and HERDOO2 are used to judge the need for long-term anticoagulation.
The key to preventing pulmonary embolism is preemptive prophylaxis in situations of high VTE risk. In surgical patients, VTE risk is stratified with the Caprini score or Rogers score, and an appropriate preventive strategy is selected. In patients undergoing high-risk orthopedic surgery (hip and knee replacement), a DOAC (rivaroxaban, apixaban) or LMWH is given for at least 10–14 days (hip replacement: up to 35 days). Mechanical prophylaxis such as intermittent pneumatic compression devices (IPC) and elastic stockings is used as an adjunct to pharmacological prophylaxis or as an alternative in patients at high risk of bleeding.
In medical inpatients with restricted mobility and an acute medical illness, VTE prophylaxis with LMWH or a direct factor Xa inhibitor (betrixaban, apixaban) is recommended. Early ambulation is the most basic preventive measure, reducing VTE risk by decreasing venous stasis. In cancer patients at high VTE risk during outpatient chemotherapy (Khorana score ≥2), DOAC (apixaban, rivaroxaban) prophylaxis is considered.
In patients with hereditary thrombophilia, prophylactic anticoagulation is given in provoking situations such as surgery, pregnancy, and oral contraceptive use. In pregnant women with high-risk thrombophilia (antithrombin deficiency, protein C/S deficiency, homozygous Factor V Leiden, antiphospholipid syndrome), LMWH prophylaxis is given throughout pregnancy and up to 6 weeks postpartum. For long-distance travel, adequate fluid intake, regular leg movement, and, in people at high VTE risk, wearing elastic stockings are recommended.
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2020;41(4):543-603. DOI: 10.1093/eurheartj/ehz405. PMID: 31504429.
Tritschler T, Kraaijpoel N, Le Gal G, Wells PS. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018;320(15):1583-1594. DOI: 10.1001/jama.2018.14346. PMID: 30326130.
Piazza G, Goldhaber SZ. Acute pulmonary embolism: Part I: epidemiology and diagnosis. Circulation. 2006;114(2):e28-e32. DOI: 10.1161/CIRCULATIONAHA.106.620872. PMID: 16847150.
Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine. 2012;366(21):1959-1967. DOI: 10.1056/NEJMoa1114238. PMID: 22621626.
Jimenez D, Garcia-Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019. Chest. 2021;159(3):1182-1196. DOI: 10.1016/j.chest.2020.11.005. PMID: 33217420.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine. 2013;369(9):799-808. DOI: 10.1056/NEJMoa1302507. PMID: 23808982.
Mavromanoli AC, Barco S, Valerio L, et al. Rivaroxaban versus standard of care for symptomatic subsegmental pulmonary embolism. Journal of the American College of Cardiology. 2022;80(13):1278-1288. DOI: 10.1016/j.jacc.2022.07.012. PMID: 36137674.
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed. Chest. 2012;141(2 Suppl):e195S-e226S. DOI: 10.1378/chest.11-2296. PMID: 22315261.
Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006;113(4):577-582. DOI: 10.1161/CIRCULATIONAHA.105.592592. PMID: 16432070.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. PMID: 36017548.